Gene expression profiles as prognostic factors in patients with multiple myeloma treated with conventional versus novel agents in correlation with outcome

被引：0
|
作者：
Broyl, Annemiek [1 ]
Hose, Dirk [3 ]
De Knegt, Yvonne [1 ]
Lokhorst, Henk [2 ]
Goldschmidt, Hartmut
Van Duin, Mark [1 ]
Sonneveld, Pieter [1 ]
机构：
[1] Erasmus MC, Rotterdam, Netherlands
[2] Univ Med Ctr Utrecht, Utrecht, Netherlands
[3] Univ Heidelberg, Heidelberg, Germany
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.3173.3173
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3173
引用
收藏
页码：932A / 932A
页数：1
相关论文
共 50 条
  • [21] Outcome and Prognostic Factors of 17p Deleted Multiple Myeloma Patients
    Kull, Miriam
    Teleanu, Veronica
    Hayde, Daniela
    Wildbihler, Katrin
    Harsdorf, Stephanie
    Bunjes, Donald
    Liebisch, Peter
    Langer, Christian
    BLOOD, 2014, 124 (21)
  • [22] Outcome and prognostic factors of 17p deleted multiple myeloma patients
    Kull, M.
    Teleanu, V
    Schwarzwaeldr, P.
    Wildbihler, K.
    Hayde, D.
    Kolmus, S.
    Greiner, A.
    Liebisch, P.
    Langer, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 18 - 18
  • [23] The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea
    Kim, Cheolsu
    Lee, Ho Sup
    Min, Chang-Ki
    Lee, Je Jung
    Kim, Kihyun
    Yoon, Dok Hyun
    Eom, Hyeon Seok
    Lee, Hyewon
    Lee, Won Sik
    Shin, Ho-Jin
    Lee, Ji Hyun
    Park, Yong
    Jo, Jae-Cheol
    Do, Young Rok
    Mun, Yeung-Chul
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2015, 30 (05): : 675 - 683
  • [24] Multiple Myeloma with Hyperammonemia Treated with Novel Agents: A Case Series of Three Patients
    Nakamura, Hajime
    Takada, Kohichi
    Murase, Kazuyuki
    Ikeda, Hiroshi
    Iyama, Satoshi
    Manabe, Tatsuo
    Kobune, Masayoshi
    INTERNAL MEDICINE, 2023, 62 (05) : 775 - 778
  • [25] DIFFERENT PATTERN OF RELAPSE IN MULTIPLE MYELOMA (MM) PATIENTS TREATED WITH NOVEL AGENTS
    Farina, G.
    Piano, S.
    Giordano, G.
    Grafone, T.
    Nicci, C.
    Storti, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 626 - 626
  • [26] Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
    Phoebe A. Huang
    Shaunna L. Beedie
    Cindy H. Chau
    David J. Venzon
    Sheryl Gere
    Dickran Kazandjian
    Neha Korde
    Sham Mailankody
    Ola Landgren
    William D. Figg
    Scientific Reports, 9
  • [27] BONE MARROW RETICULIN FIBROSIS AS A PROGNOSTIC MARKER IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED IN THE ERA OF NOVEL AGENTS
    Suriu, C.
    Livne, M.
    Sonkin, V.
    Akria, L.
    Barhoum, M.
    Braester, A.
    HAEMATOLOGICA, 2016, 101 : 793 - 793
  • [28] Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
    Huang, Phoebe A.
    Beedie, Shaunna L.
    Chau, Cindy H.
    Venzon, David J.
    Gere, Sheryl
    Kazandjian, Dickran
    Korde, Neha
    Mailankody, Sham
    Landgren, Ola
    Figg, William D.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [29] Livin gene expression in breast carcinoma: Correlation with prognostic factors and patient outcome
    Abdallah, D.
    Soliman, K.
    Khedr, G.
    VIRCHOWS ARCHIV, 2016, 469 : S237 - S238
  • [30] CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome
    Koumpis, Epameinondas
    Tassi, Iliana
    Malea, Theodora
    Papathanasiou, Konstantina
    Papakonstantinou, Ioannis
    Serpanou, Anastasia
    Tsolas, Evangelos
    Kapsali, Eleni
    Vassilakopoulos, Theodoros P.
    Papoudou-Bai, Alexandra
    Hatzimichael, Eleftheria
    PATHOLOGY RESEARCH AND PRACTICE, 2021, 225
12345